Longitudinal studies of angiogenesis in hormone-dependent Shionogi tumors.
Vessel size imaging was used to assess changes in the average vessel size of Shionogi tumors throughout the tumor growth cycle. Changes in R(2) and R(2)* relaxivities caused by the injection of a superparamagnetic contrast agent (ferumoxtran-10) were measured using a 2.35-T animal magnetic resonance imaging system, and average vessel size index (VSI) was calculated for each stage of tumor progression: growth, regression, and relapse. Statistical analysis using Spearman rank correlation test showed no dependence between vessel size and tumor volume at any stage of the tumor growth cycle. Paired Student's t test was used to assess the statistical significance of the differences in average vessel size for the three stages of the tumor growth cycle. The average VSI for regressing tumors (15.1 +/- 6.6 microm) was significantly lower than that for growing tumors (35.2 +/- 25.5 microm; P < .01). Relapsing tumors also had an average VSI (45.4 +/- 41.8 microm) higher than that of regressing tumors, although the difference was not statistically significant (P = .067). This study shows that VSI imaging is a viable method for the noninvasive monitoring of angiogenesis during the progression of a Shionogi tumor from androgen dependence to androgen independence.
Wade
Trevor P
TP
Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada.
Kozlowski
Piotr
P
D000818:Animals; D003287:Contrast Media / Q000008:administration & dosage; D003911:Dextrans; D004195:Disease Models, Animal; D052203:Ferrosoferric Oxide; D007501:Iron; D008137:Longitudinal Studies; D018810:Magnetic Resonance Angiography / Q000379:methods*; D058185:Magnetite Nanoparticles; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D009368:Neoplasm Transplantation; D009376:Neoplasms, Hormone-Dependent / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000175:diagnosis* / Q000473:pathology; D010087:Oxides; D011471:Prostatic Neoplasms / Q000098:blood supply*
D003287:Contrast Media; D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; C097921:ferumoxtran-10; D007501:Iron; D052203:Ferrosoferric Oxide
J Natl Cancer Inst. 2000 Jan 5;92(1):34-41
10620631
Neoplasia. 2007 May;9(5):382-91
17534443
Magn Reson Med. 2001 Mar;45(3):397-408
11241696
Nat Med. 2001 Sep;7(9):987-9
11533692
Nat Rev Drug Discov. 2002 Jun;1(6):415-26
12119743
J Magn Reson Imaging. 2003 Apr;17(4):445-54
12655584
Cancer Res. 2003 Aug 15;63(16):4960-6
12941821
CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29
14974761
Magn Reson Med. 2004 Mar;51(3):533-41
15004795
J Pathol. 1975 Jun;116(2):65-72
168332
Cancer Res. 1988 Nov 15;48(22):6309-12
2460222
Cancer Res. 1989 Dec 1;49(23):6449-65
2684393
Magn Reson Med. 1992 Apr;24(2):375-83
1569876
Nature. 1992 Oct 29;359(6398):843-5
1279431
Am J Pathol. 1993 Aug;143(2):401-9
7688183
Magn Reson Imaging. 1995;13(5):661-74
8569441
Prostate. 1998 Apr 1;35(1):1-10
9537593
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10820-5
9724788
Magn Reson Med. 1998 Dec;40(6):793-9
9840821
J Urol. 1999 Mar;161(3):960-3
10022734
Magn Reson Med. 1999 Mar;41(3):499-509
10204873
Magn Reson Med. 1999 Oct;42(4):754-61
10502765
MAGMA. 2004 Dec;17(3-6):313-6
15580376
BJU Int. 2005 Mar;95(4):644-9
15705096
Magn Reson Med. 2005 Mar;53(3):553-63
15723391
Neoplasia. 2005 Sep;7(9):847-53
16229807
Nature. 2000 Sep 14;407(6801):249-57
11001068